Bringing 25 years’ experience in the art market, Rachel provides appraisals for estate tax, charitable donation, insurance and collateral loans and advises private clients on acquiring and deaccessioning works of art.īefore joining Gurr Johns, Rachel spent 9 years as Vice President of Contemporary Art at Sotheby’s where she led both the day and evening sales during a time of rapid market expansion. Medical Affairs offers a complete solution for pre and post-marketing communications between internal and external stakeholders.Senior Director of Fine Art Advisory & Appraisals New Adler Rosan joined Gurr Johns in March 2022 as Senior Director of Fine Art, specialising in 20 th Century and Contemporary Art. Pharmacovigilance & Risk Management offers a modern clinical safety and pharmacovigilance platform to improve compliance with global regulatory guidelines. Regulatory Affairs is a suite of next generation solutions for regulatory compliance that integrates compliance with business processes over the entire product management lifecycle. To be the most powerful engine for advancement in the Life Sciences industryĬlinical Development provides solutions for clinical operations combined with clinical data management to offer the most complete clinical research platform in the industry. To consistently deliver actionable insights, boost efficiency, and ensure compliance, all while lowering total cost of ownership The company believes Life Sciences companies must automate all core functions to succeed in an increasingly complex global market. The company has never stopped growing or innovating, bringing improvements in efficiencies, regulatory compliance and the best technology to its customers. ArisGlobal was the first PV technology provider to enter Japan and today the company has more relationships with health authorities across the globe than any other vendor on the market to manage public health safety. The company has over 30 years in delivering innovative solutions to a highly regulated and complex space with many “firsts” in its ongoing market leadership.ĪrisGlobal was first to market with E2B in the year 2000 when new regulations were introduced, and most recently the company was the first to offer E2B R3 requirements in its products and first to market with an IDMP solution. ArisGlobal is a pioneer in the safety and pharmacovigilance space, bringing the first commercially available drug safety system to the life sciences industry.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |